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Abstract: The aim of this study was to characterize the relationship between the intake of the major
nutrients and prognosis in breast cancer. A cohort based on 1350 women with invasive (stage I-IV)
breast cancer (BC) was followed up. Information about their dietary habits before diagnosis was
collected using a semi-quantitative Food Frequency Questionnaire. Participants without FFQ or with
implausible energy intake were excluded. The total amount consumed of each nutrient (Kcal/day)
was divided into tertiles, considering as “high intakes” those above third tertile. The main effect
studied was overall survival. Cox regression was used to assess the association between death
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and nutrient intake. During a median follow-up of 6.5 years, 171 deaths were observed. None of
the nutrients analysed was associated with mortality in the whole sample. However, in normal-
weight women (BMI 18.5–25 kg/m2) a high intake of carbohydrates (≥809 Kcal/day), specifically
monosaccharides (≥468 Kcal/day), worsened prognostic compared to lowest (≤352 Kcal/day).
Hazard Ratios (HRs) for increasing tertiles of intake were HR:2.22 95% CI (1.04 to 4.72) and HR:2.59
95% CI (1.04 to 6.48), respectively (p trend = 0.04)). Conversely, high intakes of polyunsaturated fats
(≥135 Kcal/day) improved global survival (HR: 0.39 95% CI (0.15 to 1.02) p-trend = 0.05) compared
to the lowest (≤92.8 kcal/day). In addition, a protective effect was found substituting 100 kcal
of carbohydrates with 100 kcal of fats in normal-weight women (HR: 0.76 95% CI (0.59 to 0.98)).
Likewise, in premenopausal women a high intake of fats (≥811 Kcal/day) showed a protective effect
(HR:0.20 95% CI (0.04 to 0.98) p trend = 0.06). Finally, in Estrogen Receptors (ER) negative tumors,
we found a protective effect of high intake of animal proteins (≥238 Kcal/day, HR: 0.24 95% CI
(0.06 to 0.98). According to our results, menopausal status, BMI and ER status could play a role in
the relationship between diet and BC survival and must be taken into account when studying the
influence of different nutrients.
Keywords: breast cancer; dietary nutrients; overall survival; prognosis; mortality
1. Introduction
Breast cancer (BC) is the most frequently diagnosed cancer in women and the leading
cause of cancer death worldwide [1,2] as well as in all European Countries [2]. In Europe,
the overall survival rate of BC has improved in the last few decades. This favourable trend
can be explained in part by both the advances in the treatment and management of BC over
the last three decades [3,4], and, in women aged 50 and above, the development of screening
programs. However, there are still noticeable differences between countries across Europe.
Countries in Southern Europe (Spain and Portugal) and Nordic countries (Norway and
Finland) show the lowest mortality rates, whereas countries in the Balkan Peninsula and
parts of Eastern Europe (Hungary and Moldova) roughly double this mortality rate [5].
These differences have led to speculation that, beyond the major prognosis factors of
BC, individual’s lifestyle (diet, physical exercise, etc.) may also play a key role in cancer
survivorship [6].
Focusing on diet, several studies have proposed different mechanisms to explain
the potential role of specific nutrients on cancer prognosis. Regarding fat intake, mo-
nounsaturated fats can have a protective effect due to their influence on tumor associated
macrophages, promoting a change in polarization from M2 to M1 macrophages, thus
leading to better prognosis [7]. Likewise, the consumption of foods rich in omega 3 such as
bluefish, salmon, vegetable oils and nuts has been previously associated with better prog-
nosis in women with node-negative disease [8]. Moreover, a high omega 3/omega 6 ratio
has been associated with a better prognosis of BC [9], while saturated fats could have a
deleterious effect on BC survival, by increasing circulating levels of endogenous estrogen,
insulin-like growth factor (IGF)-1, and pro-inflammatory cytokines [10].
As for other nutrients, high animal-protein diets may accelerate insulin-like growth factor-
1 (IGF-1) secretion, promoting cancer incidence and progression [11], and carbohydrate-rich
diets could be associated with BC prognosis through different mechanisms. Monosaccharides
could worsen BC prognosis by activating the insulin-IGF-1 axis and employing aerobic
glycolysis as the primary energy harvesting pathway (Warburg effect). On the contrary,
polysaccharides could improve BC prognosis by disrupting the insulin/IGF-1 axis, decreas-
ing bioavailable androgenic and estrogenic factors, increasing fecal excretion of carcinogens,
and modulating the gastrointestinal microbiota [12].
Improving the knowledge of the role of diet on BC prognosis will allow women to
take part in increasing their chances of survival by adopting healthier habits. However,
up to this date, the research on the influence of specific nutrients on BC prognosis has not
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obtained consistent findings [10]. The last report of the Continuous Update Project suggests
that a diet rich in fiber (both before and after diagnosis), and soy (after diagnosis) could
be associated with better BC survival. In contrast, a high intake of fats before developing
the disease, especially saturated fats, seems to be associated with poorer survival rate [13].
Due to the lack of consistency in the results, additional research in this topic is required.
Besides, the influence of potential interaction factors such as BMI or hormonal receptors has
been scarcely studied to date. Menopausal status has been identified as an effect modifier in
the relationship between fiber intake and BC prognosis [13] and between carbohydrates [14]
and BC risk. Regarding hormone receptors, some studies have suggested that lifestyle risk
factors, including diet, may have a comparatively greater influence in the development of
ER− subtype than ER+ [15]. The Women’s Intervention Nutrition Study (WINS) [16], found
a positive effect of reducing dietary fat intake on relapse-free survival of BC, and this effect
was mainly noted in the subgroup with ER− tumors. Two large studies had identified
obesity as an effect modifier in the relation between diet and BC: the E3N French study [14]
aimed to investigate the effect of carbohydrates on BC risk, and the Women’s Health
Initiative Randomized Controlled Trial focus aimed to do the same on fats [17]. Thus, it has
been speculated that the relation between nutritional factors and BC could be modulated
by obesity because of the effect of adiposity and, in particular, central adiposity on insulin
resistance [14]. In this context, the aim of our study is to characterize the relationship
between the intake of the major nutrients and prognosis in BC related to each women’s
specific characteristics.
2. Materials and Methods
2.1. Study Population
The MCC-Spain breast cancer follow-up study is a prospective cohort study that comes
from the MCC-Spain project. This project began in 2008 with the aim of investigating the
relationship between genetic and environmental exposures and cancer development [18].
In 2016, the MCC-Spain project turned towards the identification of factors associated
with cancer prognosis using the incident cases originally recruited between 2008 and 2013.
Our initial cohort consists of 1685 incident BC cases recruited, and follow-up in 18 hospitals
of 10 Spanish provinces (Asturias, Barcelona, Cantabria, Girona, Gipuzkoa, Huelva, León,
Madrid, Navarra and Valencia) in the MCC-Spain project. Further information can be
found elsewhere [19,20]. From this initial cohort we exclude the following participants:
(1) those with non-invasive tumors, (2) those without food frequency questionnaire (FFQ)
and (3) those with implausible energy intakes (<750 or ≥4500 kcal) in the FFQ. 1350 women
fulfilled the inclusion criteria of the current analysis. The process is summarized in the
study flow-chart (Figure 1).
2.2. Ethical Approval
The Ethics Committees of participating hospitals approved the study protocols of
MCC-Spain [18]. (code for the ethics committee of Cantabria: September 2016) and par-
ticipants were provided with written informed consent at the time of their enrolment in
the study, which also included the authorization for following up the patients via medical
records or phone calls; only participants agreeing to being followed up were included
in the inception cohorts. The database was registered with the Spanish Agency for Data
Protection, number 2102672171. Permission to use the study database will be granted to
researchers outside the study group after revision and approval of each request by the
Steering Committee.
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Figure 1. Study flowchart.
2.3. Dietary and Prognosis Factors Assessment
The information on pre-diagnosis diet was collected using a food-frequency question-
naire (FFQ) previously validated for the Spanish population [21]. In the FFQ, patients were
asked about their eating habits during the previous year. The FFQ included 140 items.
Each participant received the FFQ at the end of the interview in paper format, to be com-
pleted at home and returned by mail. The food composition table was a compiled table
from CESNID Food Composition Table [22]. Cross-check questions were used to adjust
the frequency of foods eaten and reduce overreporting of food groups with large numbers
of items [23]. The food composition table was used to obtain daily intake of main nutri-
ent groups: carbohydrates, proteins and fats. Besides, carbohydrates and proteins were
subdivided into two subtypes according to their type (monosaccharide or polysaccharide)
or their source (animal or vegetable) respectively, and fats into three (monounsaturated,
saturated and polyunsaturated). The total amount consumed of each nutrient (Kcal/day)
was divided into tertiles.
Covariate assessment information which may specifically be related to BC prognosis
includes: sociodemographic factors (age at diagnosis, education attained, socioeconomic
status), family history of breast cancer, anthropometric data and lifestyle (tobacco, phys-
ical activity: metabolic equivalents, constructed with data on reported level of physical
activity during the last five years—excluding the one year before the interview). This in-
formation was gathered in a face-to-face interview using a standardized questionnaire
administered by trained personnel. The clinical and anatomopathological characteristics
of the tumor and the systemic treatment received were obtained by review of the medical
records. The clinical-pathological data form includes tumor location and size, invasiveness,
histological type, degree of differentiation, vascular or lymphatic infiltration, number of
affected lymph nodes, infiltration of resection margins, hormonal receptors, C-ErbB2 by
immunohistochemistry or Fluorescent in situ hybridization ( FISH), Ki-67, clinical TNM (be-
fore treatment) and surgical stage. The Pathological Prognosis Stage (PPS) was calculated
in those women with BC treated with surgery as initial treatment; this includes clinical
staging information, findings at surgery and pathological findings [24]. Finally, systemic
treatment received includes chemotherapy, hormone therapy, and immunotherapy.
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2.4. Follow-Up and Ascertainment of Events
Follow-up was carried-out between 2017 and 2018 by reviewing medical records and
contacting the participants by telephone. The main effect was death. Events of death were
consulted in the medical record or in the Spanish National Death Index (a nation-wide
data-base supported by the Spanish Ministry of Health) when medical records do not
provide them, and in women whose last contact with the hospital had occurred three or
more months before our revision of her medical record [25].
2.5. Statistical Analysis
An overall survival analysis was carried out in which the main effect variable was all
causes of death, and patients who remain alive after the end of follow-up were considered
censored. Withdrawals were censored at the date of last contact with the patient. Time of
follow-up was calculated as the difference between date of diagnosis and date of death or
date of last contact. Cox regression was used to assess the association between death and
nutrient intake; results are reported as hazard ratio (HR) with confidence interval (95% CI).
Three different types of adjustment were made; for age, total energy intake (Kcal/day) [26],
and the main clinical factors related to BC prognosis, hospital of recruitment, PPS and
the systemic treatment received by the patients (chemotherapy, hormone therapy or im-
munotherapy). PPS could only be established for women without neoadjuvant therapy.
Therefore, when adjusting for PPS two additional categories were included: one for women
with neoadjuvant therapy and another for those women whose PPS could not be deter-
mined, in spite of having no neoadjuvant therapy. In the second model, anthropometric
data (BMI), lifestyle factors (consumption of tobacco and metabolic equivalents—METS)
and sociodemographic factors (socioeconomic score and education) were added to the
variables adjusted for in the first model; and in the third model, a specific adjustment by
nutrients was added to the previous ones. Each type of main group of nutrients (carbo-
hydrates, proteins and fats) was adjusted for the percentage calories from the other types.
Finally, mutual adjustment was subsequently added for animal protein and plant protein,
short and long chain carbohydrate, and the different type of fats, respectively. This strategy
of adjustment simulates an energy substitution model. Lastly, a stratified analysis was
carried out by three potential effect modifiers: menopausal status at diagnosis, body mass
index (BMI) and Estrogen receptors (ER). Two-tailed P values for linear trend tests across
tertiles were calculated.
In order to find out the consequences of replacing nutrients on BC survival, a substitu-
tion analysis was carried out. The effect of substituting one type of nutrient for another
was calculated by estimating a substitution model with constant total energy consumption,
following the method proposed by Willet et al. [26,27].
To do so, the initial model was:
log = + β1 × carbohydrates + β2 × proteins + β3 × f ats+β4 × total energy + β5 × covariates
This model cannot be estimated because of the linear relationship between the regres-
sors (i.e., total nutrients = carbohydrates + proteins + fats).
By omitting a term, say carbohydrates, the estimated model indicates the effect of
substituting an amount of carbohydrates by equal amounts of proteins or fats, as the model
keeps the total energy intake constant. This method is an iso-temporal model that allows
the estimation of the effect of substituting a fixed amount of a type of nutrient for another.
Our sample size (1350 women) had 85% power to detect hazard ratio >1.7 or <0.59
(=1/1.7).
We have carried out a sensitivity analysis excluding advanced BC (stage IV) at diagno-
sis. Analyses were performed using the package Stata 16/SE (Stata Corp, College Station,
TX, USA).
3. Results
A total of 1350 women diagnosed with BC were included in this study. The me-
dian follow-up time was 6.5 years. 171 deaths occurred during follow-up. These women
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had, at enrolment, an average age of 55.84 years (SD: 12.5); 487 cases (36.1%) were pre-
menopausal women. Supplementary Table S1 summarizes the main characteristic of the
tumors. 63.2% tumors were luminal A-like, and 19.3% luminal B-like. The majority of
cases were diagnosed at early stages. Fifty-two of the 726 women diagnosed in early stages
(I–II) had BC recurrence. Supplementary Table S2 summarizes the dietary constituents
in the whole cohort and in the two subgroups of women who died and survived at the
end of follow-up. The mean intake of carbohydrates, proteins, and fats were respectively
(192.6 g/day, 80.2 g/day, and 83.2 g/day). No significant differences were found in the
intake of nutrients between women who died and those who survived. Supplementary
Table S3 shows the main characteristics of the study population according to tertiles of
energy intake. In those women with high energy intake (third tertile), there was a higher
percentage of premenopausal women. In women with low energy intake, lower percent-
ages of university studies and a high socioeconomic status was found. No differences
in previous use of hormonal contraceptive or hormone replacement therapy were found.
On average, women with higher energy intake were younger and had lower BMI and
higher alcohol intake.
3.1. Relationship between Carbohydrate Intake and Overall Survival
Although carbohydrate intake or its different subtypes did not have an effect on
survival in the whole sample with BC (Table 1), in normal-weight women (BMI ≤ 25) high
consumption of carbohydrate showed a strong association with mortality irrespectively of
the model of adjustment (HR: 3.36 95% CI (1.01 to 11.2) in the third model). This deleterious
effect was restricted to monosaccharides intake showing a significant linear trend (HR:
2.22 95% CI (1.04 to 4.72) for moderate intake and HR: 2.59 95% CI (1.04 to 6.48) for high
intake, p trend = 0.04). On the other hand, in overweight or obese women no relationship
was found between total carbohydrates intake and mortality (HR: 1.19 95% CI (0.48 to 2.95)
(Figure 2). However, moderate and high intake of monosaccharides showed protection in
the first (HR:0.50 95% CI (0.29 to 0.89) for moderate intake and HR: 0.45 95% CI (0.23 to 0.91)
for high intake, p trend = 0.03); and the second model of adjustment (HR: 0.53 95% CI
(0.29 to 0.95) for moderate intake and HR: 0.50 95% CI (0.24 to 1.02) for high intake,
p trend = 0.06), but this finding did not reach statistical significance, adjusting the effect for
polysaccharides intake and diabetes (model 3 HR: 0.60 95% CI (0.33 to 1.10) for moderate
intake, and HR: 0.57 95% CI (0.22 to 1.19) for high intake, p trend = 0.14) (Figure 2).
In contrast, menopausal status and ER did not modify the effect observed in the whole
population (Figure 2, Supplementary Table S4).
3.2. Relationship between Protein Intake and Overall Survival
Total protein intake or its subtypes were not associated with the overall survival of
BC (Table 1). However, when we analyze animal protein intake separately, we observed a
differential effect according to menopausal status. In postmenopausal women, we found a
higher risk associated with moderate intake (HR: 1.88 95% CI (1.17 to 3.04)) that disappeared
in premenopausal women. In contrast, stratifying by ER, in ER-tumors a high animal
protein intake showed an inverse association with BC mortality (HR: 0.24 95% CI (0.06 to
0.99)). No interaction with BMI was observed (Figure 3). On the other hand, a moderate
intake of vegetable protein diminished the risk of dying among premenopausal women
regardless of the model of adjustment used (HR:0.35 95% CI (0.14 to 0.86) in the third
model), which disappeared in postmenopausal women. No differential effect was observed
according to BMI or ER status (Figure 3, Supplementary Table S5).
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Table 1. Influence of nutrient intake on breast cancer survival. Hazard ratios comparing third and second tertiles vs. first tertile of
consumption.
Type of Nutrient 1st Tertile HR (95% CI) 2nd Tertile HR (95% CI) 3rd Tertile p Trend
Total carbohydrates Deaths/woman-years 52/2933 53/2946 66/2913
Model 1 1(ref.) 1.10 (0.72 to 1.68) 1.36 (0.80 to 2.33) 0.27
Model 2 1(ref.) 1.09 (0.71 to 1.67) 1.31 (0.76 to 2.26) 0.34
Model 3 * 1(ref.) 1.12 (0.71 to 1.75) 1.42 (0.75 to 2.69) 0.30
Monosaccharides Deaths/woman-years 56/2910 55/2943 60/2939
Model 1 1(ref.) 0.86 (0.58 to 1.29) 0.76 (0.47 to 1.24) 0.28
Model 2 1(ref.) 0.86 (0.58 to 1.30) 0.75 (0.45 to 1.22) 0.24
Model 3 # 1(ref.) 0.89 (0.59 to 1.35) 0.74 (0.45 to 1.23) 0.25
Polysaccharides Deaths/woman-years 54/2984 65/2870 52/2937
Model 1 1(ref.) 1.25 (0.85 to 1.85) 0.94 (0.58 to 1.52) 0.84
Model 2 1(ref.) 1.23 (0.83 to 1.83) 0.96 (0.59 to 1.55) 0.91
Model 3 $ 1(ref.) 1.24 (0.83 to 1.84) 0.92 (0.56 to 1.50) 0.77
Total proteins Deaths/woman-years 60/2888 52/2956 59/2948
Model 1 ** 1(ref.) 0.89 (0.59 to 1.34) 0.96 (0.56 to 1.62) 0.84
Model 2 1(ref.) 0.88 (0.58 to 1.33) 0.96 (0.56 to 1.64) 0.84
Model 3 1(ref.) 0.94 (0.61 to 1.45) 1.12 (0.61 to 2.06) 0.77
Animal proteins Deaths/woman-years 52/2928 64/2902 55/2962
Model 1 1(ref.) 1.37 (0.92 to 2.04) 1.13 (0.70 to 1.82) 0.60
Model 2 1(ref.) 1.37 (0.91 to 2.06) 1.09 (0.68 to 1.76) 0.72
Model 3 ¥ 1(ref.) 1.35 (0.89 to 2.03) 1.05 (0.64 to 1.71) 0.84
Vegetable proteins Deaths/woman-years 62/2894 52/2965 57/2932
Model 1 1(ref.) 0.88 (0.59 to 1.32) 0.75 (0.46 to 1.23) 0.26
Model 2 1(ref.) 0.91 (0.61 to 1.37) 0.79 (0.48 to 1.30) 0.35
Model 3 £ 1(ref.) 0.90 (0.60 to 1.35) 0.77 (0.46 to 1.28) 0.32
Total fats Deaths/woman-years 59/2902 59/2913 53/2976
Model 1 1(ref.) 0.77 (0.51 to 1.17) 0.70 (0.37 to 1.30) 0.22
Model 2 1(ref.) 0.80 (0.52 to 1.22) 0.73 (0.39 to 1.37) 0.30
Model 3 ** 1(ref.) 0.73 (0.45 to 1.19) 0.63 (0.30 to 1.34) 0.22
Saturated fats Deaths/woman-years 63/2909 56/2909 52/2974
Model 1 1(ref.) 0.79 (0.52 to 1.20) 0.76 (0.41 to 1.40) 0.33
Model 2 1(ref.) 0.78 (0.51 to 1.18) 0.73 (0.39 to 1.36) 0.27
Model 3 § 1(ref.) 0.74 (0.48 to 1.14) 0.70 (0.37 to 1.31) 0.22
Monounsaturated
fats Deaths/woman-years 56/2901 64/2926 51/2965
Model 1 1(ref.) 0.95 (0.63 to 1.43) 0.74 (0.43 to 1.28) 0.29
Model 2 1(ref.) 0.99 (0.65 to 1.49) 0.77 (0.44 to 1.33) 0.36
Model 3 ¶ 1(ref.) 1.00 (0.66 to 1.53) 0.78 (0.44 to 1.38) 0.41
Polyunsaturated fats Deaths/woman-years 60/2855 61/2984 50/2952
Model 1 1(ref.) 0.87 (0.58 to 1.30) 0.76 (0.45 to 1.28) 0.3
Model 2 1(ref.) 0.90 (0.59 to 1.35) 0.81 (0.48 to 1.37) 0.44
Model 3 ß 1(ref.) 0.86 (0.56 to 1.31) 0.77 (0.45 to 1.32) 0.34
HR: Hazard ratio. 95% CI: 95% confidence interval. Model 1: Adjusted for hospital of recruitment, age, PPS score (0, IA, IB, IIA, IIB, IIA,
IIB, IIC, IV, non-applicable, missing), systemic treatment received by the patients: chemotherapy (yes, non), hormone therapy (yes, non)
and immunology therapy (yes, non) and total energy intake (Kcal/day) one year before the diagnosis. Model 2: Adjusted for all previous
variables and socioeconomic status (low, middle, high), education attained, physical activity (metabolic equivalents (METs)) during the
5 years before diagnosis, smoking status one year before recruitment (never; former; current) and Body Mass Index(kg/m2). Model 3:
Adjusted for the same variables as model 2 and * diabetes (yes, non, unknown), percentage of calories from the other major nutrient groups,
** percentage of calories from the other major nutrient groups, # percentage of calories from polysaccharides, $ percentage of calories from
monosaccharides, ¥ percentage of calories from vegetable protein, £ percentage of calories from animal protein, § percentage of calories
from monounsaturated and polyunsaturated fats, ¶ percentage of calories from saturated and polyunsaturated fats ß percentage of calories
from saturated and monounsaturated fats.
3.3. Relationship between Fat Intake and Overall Survival
No relationship was found between total fat intake or its different subtypes and BC
survival, irrespective of the model of adjustment used (Table 1). However, analyzing
separately by menopausal status (Figure 4), a moderate intake of fat shows a protective
effect confined to premenopausal women and only in the third model of adjustment ((HR:
0.25 95% CI (0.08 to 0.84) for moderate intake and HR: 0.20 95% CI (0.04 to 0.98) for high
intake, p trend = 0.06). On the other hand, in normal-weight women, polyunsaturated fat
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showed a protective effect with a linear trend regardless the model of adjustment (HR: 0.39
95% CI (0.15 to 1.02), p trend = 0.05 in the third model) (Figure 4). No differential effect was




Figure 2. Influence of carbohydrate intake on breast cancer survival according to (a) menopausal
status, (b) BMI and(c) estrogen receptor status. Hazard ratios comparing third and second tertiles
vs. first tertile of consumption. Adjusted for hospital of recruitment, age, PPS score (0, IA, IB,
IIA, IIB, IIA, IIB, IIC, IV, non-applicable, missing), systemic treatment received by the patients:
chemotherapy (yes, non), hormone therapy (yes, non) and immunology therapy (yes, non) and
total energy intake (Kcal/day) one year before the diagnosis, socioeconomic status (low, middle,
high), education attained, physical activity (metabolic equivalents (METs)) during the 5 years before
diagnosis, smoking status one year before recruitment (never; former; current) and Body Mass
Index (kg/m2), diabetes (yes, non, unknown) and Total carbohydrates intake was adjusted for the
percentage of calories from the other major nutrient groups; mono-saccharides and poly-sacharides
were mutually adjusted for percentage of calories.




Figure 3. Influence of protein intake on breast cancer survival according to (a) menopausal status,
(b) BMI and (c) estrogen receptor status. Hazard ratios comparing third and second tertiles vs. first
tertile of consumption. Adjusted for hospital of recruitment, age, PPS score (0, IA, IB, IIA, IIB, IIA,
IIB, IIC, IV, non-applicable, missing), systemic treatment received by the patients: chemotherapy (yes,
non), hormone therapy (yes, non) and immunology therapy (yes, non), total energy intake (Kcal/day)
one year before the diagnosis, socioeconomic status (low, middle, high), education attained, physical
activity (metabolic equivalents (METs)) during the 5 years before diagnosis, smoking status one
year before recruitment (never; former; current) and Body Mass Index (kg/m2), diabetes (yes, non,
unknown). Total protein intake was adjusted for the percentage of calories from the other major
nutrient groups. Animal and vegetable proteins were mutually adjusted for percentage of calories.




Figure 4. Influence of fat intake on breast cancer survival according to (a) menopausal status, (b) BMI
and (c) estrogen receptor status. Hazard ratios comparing third and second tertiles vs. first tertile of
consumption. Adjusted for hospital of recruitment, age, PPS score (0, IA, IB, IIA, IIB, IIA, IIB, IIC,
IV, non-applicable, missing), systemic treatment received by the patients: chemotherapy (yes, non),
hormone therapy (yes, non) and immunology therapy (yes, non) total energy intake (Kcal/day) one
year before the diagnosis, socioeconomic status (low, middle, high), education attained, physical
activity (metabolic equivalents (METs)) during the 5 years before diagnosis, smoking status one
year before recruitment (never; former; current) and Body Mass Index (kg/m2), diabetes (yes, non,
unknown). Total fat intake was adjusted for the percentage of calories from the other major nutrient
groups. Saturated, monounsaturated and polyunsaturated fats were mutually adjusted for percentage
of calories.
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No relevant differences were found in the sensitivity analysis (excluding stage IV
tumors), therefore these results are not shown.
3.4. Effect of Substituting a Nutrient for Another
Finally, we investigated the effect of substituting 100 kcal of a type of nutrient with
100 kcal of another type (Table 2). No association was observed in the whole population;
however, a protective effect was found when substituting 100 kcal of carbohydrates with
100 kcal of fats in normal weighted women (HR: 0.76 95% CI (0.59 to 0.98) (Table 3).
Table 2. Effect of replacing 100 kcal of a nutrient with 100 kcal of another nutrient.
Substituted Nutrient
Carbohydrates Proteins Fats
HR 95% CI HR 95% CI HR 95% CI
Carbohydrates 1.09 (0.78 to 1.52) 1.02 (0.90 to 1.16)
Proteins 0.94 (0.67 to 1.33) 0.96 (0.68 to 1.35)
Fats 0.99 (0.87 to 1.12) 1.07 (0.77 to 1.49)
Table 3. Effect of replacing 100 kcal of a nutrient with 100 kcal of another nutrient stratified by menopausal status, BMI and
ER status.
Substituted Nutrient
Premenopausal Women Menopausal Women
Carbohydrates Proteins Fats Carbohydrates Proteins Fats
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI





















BMI ≤ 25 BMI > 25





















ER negative ER positive





















Adjusted for: hospital of recruitment, age, PPS score (0, IA, IB, IIA, IIB, IIA, IIB, IIC, IV, missing), systemic treatment received by the
patients: chemotherapy (yes, non), hormone therapy (yes, non) and immunology therapy (yes, non), total energy intake (Kcal/day) one
year before the diagnosis, menopausal status, socioeconomic status (low, middle, high), education attained, physical activity (metabolic
equivalents (METs)) during the 5 years before diagnosis, smoking status one year before recruitment (never; former; current) and Body
Mass Index (kg/m2).
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For instance, taking 100 kcal more as proteins instead of 100 kcal as carbohydrates
gives HR = 0.94, 95% CI 0.67–1.33. Adjusted for: hospital of recruitment, age, PPS score
(0, IA, IB, IIA, IIB, IIA, IIB, IIC, IV, missing), systemic treatment received by the patients:
chemotherapy (yes, non), hormone therapy (yes, non) and immunology therapy (yes,
non), total energy intake (Kcal/day) one year before the diagnosis, menopausal status,
socioeconomic status (low, middle, high), education attained, physical activity (metabolic
equivalents (METs)) during the 5 years before diagnosis, smoking status one year before
recruitment (never; former; current) and Body Mass Index (kg/m2).
4. Discussion
Observational data has consistently linked poor dietary quality [28] and other lifestyle
factors [6,29] to increased risk of developing and dying from malignancy. However, even
though our study does not directly address the effects of lifestyle, our results do not reveal
any direct effect on BC survival of the different types of nutrients evaluated. Interestingly,
menopausal status, BMI and ER status could interact to modulate this influence.
We observed that a diet high in carbohydrate, in normal-weight women (BMI ≤ 25),
and moderate in animal-protein in postmenopausal women, worsens BC survival. In con-
trast, some types of nutrients improve survival in specific subsets of women. In pre-
menopausal women, a moderate intake of vegetable proteins and total fats seems to have a
protective effect. On the other hand, in normal-weight women, polyunsaturated fats show
protection with a significant trend.
With carbohydrates, although different mechanisms through which they could impact
on cancer progression have been identified [30], most of the epidemiological studies devel-
oped to date [31–33] and the International World Cancer Research Fund meta-analysis [34]
have obtained inconclusive results. In the same line, we did not obtain an association
between a diet high in carbohydrates and BC prognosis. However, in normal-weight
women our data show an increased risk associated with carbohydrate intake, and more
specifically to monosaccharide intake. Besides, when substituting 100 g of carbohydrates
for 100 g of fats, a protective effect was observed limited to this subgroup of women.
A possible explanation of the deleterious effect of a high carbohydrate diet could be the
increase of circulating insulin and consequently associated IGF-1, which has been related to
both the initiation and the progression of BC [35]. In addition, simple carbohydrates may
increase risk of cancer by employing aerobic glycolysis as the primary energy harvesting
pathway [12]. Nevertheless, it is somewhat paradoxical that, according to our results,
the effect of carbohydrate intake is observed only among those women with normal weight,
since a plausible mechanism in the relationship between carbohydrate intake and cancer
survival is the impaired intolerance to glucose frequently associated with obesity [36].
Besides, the serum concentrations of inflammatory cytokines, glucose, insulin and free
IGF-1 are notably elevated in obese patients and provide a pro-tumorigenic environment
that may explain the worse prognosis of obese patients with cancer. In relation to the lack
of influence of the menopausal status and ER tumors on this relationship, to the best of our
knowledge no other studies have been published taking into account menopausal or ER
status in the relationship between carbohydrates and BC prognosis. However, ER status
has been identified as an effect modifier in the relationship between IGF-1 levels and BC
risk, restricting the effect of IGF-1 levels to those ER positive tumors [37].
According to our results, protein intake does not seem to have a prognostic effect in
BC women. Consistent with this finding, several prospective studies evaluating the effect
of protein intake before diagnosis did not obtain significant results [33,38–41]. However,
some studies focusing on the role of a high protein diet after diagnosis found a survival
advantage [32,42–45]. When separately analyzing the source (animal or vegetable) of
proteins consumed, we identified interaction with menopausal and ER status. Among
postmenopausal women, we observed an increase in the mortality rate associated with a
moderate intake of protein from animal sources. Previous prospective studies aimed to
evaluate mortality in different populations have also found higher mortality rates asso-
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ciated with animal protein intake [11,46–48]. It has been speculated that a high protein
animal-based diet may accelerate IGF-1 secretion, which may promote cancer progres-
sion [11]. In contrast, the Nurses’ Health Study, a large prospective study including women
with early stages of BC [42], showed a lower risk of death resulting from BC in those
with higher animal protein intake after diagnosis, but this study did not make a stratified
analysis according to menopausal status and thus its results are not directly comparable
with ours. Regarding the influence of vegetable protein intake, we observe a protective
effect in those with a moderate intake but restricted to premenopausal women. This protec-
tion could be related to an improved insulin sensitivity in diets rich in plant proteins [49].
Consistent with our results, Song et al. [47], found that high plant protein intake was
inversely associated with all-cause mortality in a cohort of US health care professionals.
However, other studies focusing on BC prognosis show contradictory results, McEligot
et al. found that the intake of vegetables improves overall survival among postmenopausal
women [33] while the Nurses’ Health Study [42] failed to find associations. Our data show
a higher intake of vegetable proteins than that obtained by Holmes (the median value of
the fifth quintile: 36.6 g/day vs. 25.0 g/day), which could explain the differences between
both studies and the lack of association reported in the Nurses´ Health Study. On the other
hand, according to our results, the ER status seems to modify the effect of animal protein
intake. In those women with ER negative tumors a high intake of animal protein was
associated with a strong protection. This result must be interpreted cautiously given the
small number of events in this subgroup. We are not aware of any other study evaluating
this interaction; however, Holmes et al. analyzing the association between protein intake
and risk of distant recurrence did not found interactions by ER status [42].
Finally, regarding fat intake, two randomized trials addressed the impact of dietary
modification (a low-fat dietary intervention) on BC recurrence and mortality, with mixed
results. The Women’s Intervention Nutrition Study (WINS) [16], a large randomized trial
based on postmenopausal women with an early-stage BC diagnosis, obtained a longer
relapse-free survival in the intervention group (women who followed a diet with a less
total fat intake). However these results were not confirmed in the Women’s Healthy Eating
and Living Study (WHEL) [8]. In our research, no relationship with overall survival
was found with either total fat intake or its different types in the whole cohort. In line
with our results, several prospective studies focusing on both pre-diagnosis [38,50,51]
and post-diagnosis diet [8,9,16,52,53] did not find association with fat intake. In contrast,
the Women’s Health Initiative randomized clinical trial found that those postmenopausal
women randomized to a low-fat dietary pattern had increased BC overall survival [17].
Considering the role of potential interactions, menopausal status and BMI seem to modify
the effect of dietary fats intake. In premenopausal women, we found a protective effect
of both a moderate and high intake of fats (p trend = 0.06). We are not aware of other
studies focusing on premenopausal women, but it has been suggested that the association
between dairy intake (rich in saturated fat) and BC risk may differ by menopausal status,
showing an inverse association in premenopausal women [54]. On the other hand, in
normal-weight women we found protection associated with polyunsaturated intake, with a
significant trend. Polyunsaturated acids seem to have an opposite effect on carcinogenesis
and tumoral progression according to their omega-3/omega-6 composition. Diets high in
omega-3 appear to have anti-inflammatory effects, whereas omega-6-derived eicosanoids
have proinflammatory effects [55].Consistently with this hypothesis, a protective effect has
been previously found with omega-3 fatty acids [8]. Although we were not able to analyze
the omega3/omega6 composition separately, Spanish women were previously identified as
the largest consumers of fish (food rich in omega3) in the European Prospective Research
on Cancer and Nutrition (EPIC). [56,57]. To the best of our knowledge this is the first
study evaluating the prognostic effect of diet on BC developed in a Spanish population.
Our results may in part be due to differences in the contributing foods of fats in different
study population [58]. In this regard a review focused on the influence of dietary fats on
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health underlined that the types of food supplying the nutrients are more important than
the total amount of fats [59].
Our study has several strengths that should be highlighted. First, we include a
separate analysis according to potential effect modifiers (menopausal status, BMI and ER
receptors), which only few other studies have previously considered. Secondly, the use
of a FFQ (validated for a Spanish population) to assess diet information facilitates the
comparison of our results with those obtained in other studies, given that it is still the
primary dietary assessment tool in epidemiological studies [60]. Finally, the collection
of diet information before the diagnosis of BC rules out the introduction of information
biases, since the diet in the first year after diagnosis is strongly influenced by the treatment
received [61]. Despite these strengths, there are some weaknesses in our study that should
be mentioned. First, the use of FFQ could be affected by recall bias but, if it exists, it would
probably be non-differential, underestimating the associations studied. Besides, the lack
of longitudinal data on dietary consumption prevents the inclusion of dietary changes in
the analysis. This is relevant in our BC cohort, given that several studies found changes in
diet after a BC diagnosis [62,63]. Secondly, statistical power was limited for the subgroup
analyses, so we were not able to evaluate the effect of nutrients intake according to tumor
subtype. Finally, our study population was followed up for more than six years after
diagnosis; however, BC survival is often considerably longer, thus a six-year follow-up
only allowed us to investigate risk of death relatively close to diagnosis.
5. Conclusions
To sum up, according to our results, pre-diagnosis intake was not associated with a
greater risk of dying in BC women. However, it may have a relevant role in some sub-
groups of women. These findings, if confirmed, will allow BC survivors to have a more
active role in their health care. This is especially relevant in premenopausal women for
whom the advantages of screening programs remain uncertain. However, more prospective
studies are needed to confirm our results.
Supplementary Materials: The following are available online at https://www.mdpi.com/1660-460
1/18/1/84/s1, Table S1: Tumor characteristics, Table S2 Daily nutrient intake in the study population
Table S3: Baseline characteristics by tertile (T) of energy intake Table S4. Influence of carbohydrate
intake on breast cancer survival according to menopausal status, BMI and estrogen receptor status.
Hazard ratios comparing third and second tertiles vs. first tertile of consumption, Table S5. Influence
of protein intake on breast cancer survival according to menopausal status, BMI and estrogen receptor
status. Hazard ratios comparing third and second tertiles vs. first tertile of consumption, Table S6.
Influence of fat intake on breast cancer survival according to menopausal status, BMI and estrogen
receptor status. Hazard ratios comparing third and second tertiles vs. first tertile of consumption.
Author Contributions: Conceptualization, T.D.-S., I.G.-A. and J.L.; Data curation, N.G.-R., A.J.M.d.l.T.,
M.G. and G.C.-V.; Formal analysis, T.D.-S. and J.L.; Funding acquisition, M.K., M.P. and J.L.; Inves-
tigation, T.D.-S., I.G.-A. and R.C.F.; Methodology, T.D.-S., I.G.-A. and J.L.; Project administration,
G.C.-V.; Resources, J.L.; Software, J.A.-M.; Supervision, M.K. and M.P.; Validation, I.G.-A., N.G.-R.,
N.A., P.A. and P.R.-C.; Visualization, J.C. and A.M.; Writing—original draft, T.D.-S.; Writing—review
& editing, M.O.-S., G.F.-T., A.M.-B., J.A., R.M.-G., G.C.-V., B.P.-G. and J.L. All authors have read and
agreed to the published version of the manuscript.
Funding: This research was funded by the ‘Acción Transversal del Cancer’, approved by the Span-
ish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded
by FEDER funds –‘a way to build Europe’ (grants PI08/1770, PI08/0533, PI08/1359, PI09/00773,
PI09/01286, PI09/01903, PI09/02078, PI09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810,
PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/00613,
and PI15/00069). Support was also provided by the Fundación Marqués de Valdecilla (grant API
10/09); the Junta de Castilla y León (grant LE22A10-2); the Consejería de Salud of the Junta de An-
dalucía (2009-S0143); the Conselleria de Sanitat of the Generalitat Valenciana (grant AP 061/10); the
Recercaixa (grant 2010ACUP 00310); the Regional Government of the Basque Country; the Consejería
de Sanidad de la Región de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE;
Int. J. Environ. Res. Public Health 2021, 18, 84 15 of 17
the Spanish Association Against Cancer (AECC) Scientific Foundation; the Catalan Government
DURSI (grant 2014SGR647); the Fundación Caja de Ahorros de Asturias; the University of Oviedo
and COST action BM1206 Eucolongene.
Institutional Review Board Statement: The Ethics Committees of participating hospitals approved
the study protocols of MCC-Spain (code for the ethics committee of Cantabria: 2016.09). The study
was conducted according to the guidelines of the Declaration of Helsinki.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the
study.
Data Availability Statement: The database was registered with the Spanish Agency for Data Protec-
tion, number 2102672171. Permission to use the study database will be granted to researchers outside
the study group after revision and approval of each re-quest by the Steering Committee.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]
2. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Dyba, T.; Randi, G.; Bettio, M.; Gavin, A.; Visser, O.; Bray, F. Cancer incidence and
mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 2018, 103, 356–387. [CrossRef]
[PubMed]
3. Miller, K.D.; Siegel, R.L.; Lin, C.C.; Mariotto, A.B.; Kramer, J.L.; Rowland, J.H.; Stein, K.D.; Alteri, R.; Jemal, A. Cancer treatment
and survivorship statistics, 2016. CA Cancer J. Clin. 2016, 66, 271–289. [CrossRef] [PubMed]
4. Saadatmand, S.; Bretveld, R.; Siesling, S.; Tilanus-Linthorst, M.M.A. Influence of tumour stage at breast cancer detection on
survival in modern times: Population based study in 173 797 patients. BMJ 2015, 351. [CrossRef]
5. Carioli, G.; Malvezzi, M.; Rodriguez, T.; Bertuccio, P.; Negri, E.; La Vecchia, C. Trends and predictions to 2020 in breast cancer
mortality in Europe. Breast 2017, 36, 89–95. [CrossRef]
6. Lee, I.M.; Shiroma, E.J.; Lobelo, F.; Puska, P.; Blair, S.N.; Katzmarzyk, P.T.; Alkandari, J.R.; Andersen, L.B.; Bauman, A.E.;
Brownson, R.C.; et al. Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of
disease and life expectancy. Lancet 2012, 380, 219–229. [CrossRef]
7. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin.
Investig. 2007, 117, 175–184. [CrossRef]
8. Pierce, J.P.; Natarajan, L.; Caan, B.J.; Parker, B.A.; Greenberg, E.R.; Flatt, S.W.; Rock, C.L.; Kealey, S.; Al-Delaimy, W.K.; Bardwell,
W.A.; et al. Influence of a Diet Very High in Vegetables, Fruit, and Fiber and Low in Fat on Prognosis Following Treatment for
Breast Cancer. JAMA 2007, 298, 289. [CrossRef]
9. Chlebowski, R.T.; Aragaki, A.K.; Anderson, G.L.; Thomson, C.A.; Manson, J.E.; Simon, M.S.; Howard, B.V.; Rohan, T.E.; Snetselar,
L.; Lane, D.; et al. Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women’s Health Initiative Randomized Controlled
Trial. J. Clin. Oncol. 2017, 35, 2919–2926. [CrossRef]
10. De Cicco, P.; Catani, M.V.; Gasperi, V.; Sibilano, M.; Quaglietta, M.; Savini, I. Nutrition and breast cancer: A literature review on
prevention, treatment and recurrence. Nutrients 2019, 11, 1514. [CrossRef]
11. Levine, M.E.; Suarez, J.A.; Brandhorst, S.; Balasubramanian, P.; Cheng, C.W.; Madia, F.; Fontana, L.; Mirisola, M.G.; Guevara-
Aguirre, J.; Wan, J.; et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65
and younger but not older population. Cell Metab. 2014, 19, 407–417. [CrossRef] [PubMed]
12. Maino Vieytes, C.A.; Taha, H.M.; Burton-Obanla, A.A.; Douglas, K.G.; Arthur, A.E. Carbohydrate Nutrition and the Risk of
Cancer. Curr. Nutr. Rep. 2019, 230–239. [CrossRef] [PubMed]
13. World Cancer Research Fund; American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Breast Cancer.
Available online: https://www.wcrf.org/sites/default/files/Breast-Cancer-2017-Report.pdf (accessed on 27 February 2020).
14. Lajous, M.; Boutron-Ruault, M.C.; Fabre, A.; Clavel-Chapelon, F.; Romieu, I. Carbohydrate intake, glycemic index, glycemic
load, and risk of postmenopausal breast cancer in a prospective study of French women. Am. J. Clin. Nutr. 2008, 87, 1384–1391.
[CrossRef] [PubMed]
15. Du, M.; Liu, S.H.; Mitchell, C.; Fung, T.T. Associations between diet quality scores and risk of postmenopausal estrogen
receptor-negative breast cancer: A systematic review. J. Nutr. 2018, 148, 100–108. [CrossRef] [PubMed]
16. Chlebowski, R.T.; Blackburn, G.L.; Thomson, C.A.; Nixon, D.W.; Shapiro, A.; Hoy, M.K.; Goodman, M.T.; Giuliano, A.E.; Karanja,
N.; McAndrew, P.; et al. Dietary fat reduction and breast cancer outcome: Interim efficacy results from the women’s intervention
nutrition study. J. Natl. Cancer Inst. 2006, 98, 1767–1776. [CrossRef]
17. Chlebowski, R.T.; Aragaki, A.K.; Anderson, G.L.; Simon, M.S.; Manson, J.E.; Neuhouser, M.L.; Pan, K.; Stefanic, M.L.; Rohan,
T.E.; Lane, D.; et al. Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the
Women’s Health Initiative Randomized Clinical Trial. JAMA Oncol. 2018, 4, e181212. [CrossRef]
Int. J. Environ. Res. Public Health 2021, 18, 84 16 of 17
18. Castaño-Vinyals, G.; Aragonés, N.; Pérez-Gómez, B.; Martín, V.; Llorca, J.; Moreno, V.; Altzibar, J.M.; Ardanaz, E.; de Sanjosé, S.;
Jiménez-Moleón, J.J.; et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and
study design. Gac. Sanit. 2015, 29, 308–315. [CrossRef]
19. Alonso-Molero, J.; Molina, A.; Jiménez-Moleón, J.; Pérez-Gómez, B.; Martin, V.; Moreno, V.; Amiano, P.; Ardanaz, E.; de Sanjose,
S.; Salcedo, I.; et al. Cohort profile: The MCC-Spain follow-up on colorectal, breast and prostate cancers: Study design and initial
results. BMJ Open 2019, 9, e031904. [CrossRef]
20. Gómez-Acebo, I.; Dierssen-Sotos, T.; Palazuelos-Calderón, C.; Pérez-Gómez, B.; Amiano, P.; Guevara, M.; Molina, A.J.; Domingo,
L.; Fernández-Ortiz, M.; Moreno, V.; et al. Tumour characteristics and survivorship in a cohort of breast cancer: The MCC-Spain
study. Breast Cancer Res. Treat. 2020, 181, 667–678. [CrossRef]
21. García-Closas, R.; García-Closas, M.; Kogevinas, M.; Malats, N.; Silverman, D.; Serra, C.; Tardón, A.; Carrato, A.; Castaño-Vinyals,
G.; Dosemeci, M.; et al. Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. Eur. J. Cancer 2007, 43,
1731–1740. [CrossRef]
22. CESNID. Tablas de Composición de Alimentos; Ediciones de la Universitat de Barcelona, Ed.; McGraw Hill-Interamericana de España
S.A.: Barcelona, Spain, 2008.
23. Calvert, C.; Cade, J.; Barrett, J.H.; Woodhouse, A. Using cross-check questions to address the problem of mis-reporting of specific
food groups on Food Frequency Questionnaires. UKWCS Steering Group. United Kingdom Women’s Cohort Study Steering
Group. Eur. J. Clin. Nutr. 1997, 51, 708–712. [CrossRef] [PubMed]
24. Giuliano, A.E.; Edge, S.B.; Hortobagyi, G.N. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol.
2018, 25, 1783–1785. [CrossRef]
25. Navarro, C. El Índice Nacional de Defunciones: Un avance en la accesibilidad de los datos de mortalidad largamente esperado.
Gac. Sanit. 2006, 20, 421–423. [CrossRef]
26. Willett, W.C.; Howe, R. Adjustment for total energy intake in epidemiologic studies. Am. J. Clin. Nutr. 1997, 65, 1220S–1228S.
[CrossRef] [PubMed]
27. Mekary, R.A.; Willett, W.C.; Hu, F.B.; Ding, E.L. Isotemporal substitution paradigm for physical activity epidemiology and weight
change. Am. J. Epidemiol. 2009, 170, 519–527. [CrossRef] [PubMed]
28. Van Dam, R.M.; Li, T.; Spiegelman, D.; Franco, O.H.; Hu, F.B. Combined impact of lifestyle factors on mortality: Prospective
cohort study in US women. BMJ 2008, 337, 742–745. [CrossRef]
29. MacMahon, S.; Baigent, C.; Duffy, S.; Rodgers, A.; Tominaga, S.; Chambless, L.; De Backer, G.; De Bacquer, D.; Kornitzer, M.;
Whincup, P.; et al. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective
studies. Lancet 2009, 373, 1083–1096. [CrossRef]
30. Leturque, A.; Brot-Laroche, E.; Le Gall, M. Carbohydrate intake. In Progress in Molecular Biology and Translational Science; Elsevier:
Amsterdam, The Netherlands, 2012; Volume 108, pp. 113–127.
31. Saxe, G.A.; Rock, C.L.; Wicha, M.S.; Schottenfeld, D. Diet and risk for breast cancer recurrence and survival. Breast Cancer Res.
Treat. 1999, 53, 241–253. [CrossRef]
32. Goodwin, P.J.; Ennis, M.; Pritchard, K.I.; Koo, J.; Trudeau, M.E.; Hood, N. Diet and breast cancer: Evidence that extremes in diet
are associated with poor survival. J. Clin. Oncol. 2003, 21, 2500–2507. [CrossRef]
33. Jaiswal McEligot, A.; Largent, J.; Ziogas, A.; Peel, D.; Anton-Culver, H. Dietary Fat, Fiber, Vegetable, and Micronutrients Are
Associated with Overall Survival in Postmenopausal Women Diagnosed with Breast Cancer. Nutr. Cancer 2006, 55, 132–140.
[CrossRef]
34. Norat, T.; Chan, D.; Vieira, A.R.; Aune, D.; Navarro Rosenblatt, D.; Vingeliene, S.; Abar, L.; Vieira, R.; Thompson, R.; Greenwood,
D.C. Systematic Review on Diet, Nutrition, Physical Activity and Survival and Second Cancers in Breast Cancer Survivors; Imperial
College London: London, UK, 2014; p. 459.
35. Wang, J.; Luo, X.-X.; Tang, Y.-L.; Xu, J.-X.; Zeng, Z.-G. The prognostic values of insulin-like growth factor binding protein in breast
cancer. Medicine 2019, 98, e15561. [CrossRef] [PubMed]
36. Krone, C.A.; Ely, J.T.A. Controlling hyperglycemia as an adjunct to cancer therapy. Integr. Cancer Ther. 2005, 4, 25–31. [CrossRef]
[PubMed]
37. Endogenous Hormones and Breast Cancer Collaborative Group; Key, T.J.; Appleby, P.N.; Reeves, G.K.; Roddam, A.W. Insulin-like
growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: Pooled individual data analysis of 17 prospective
studies. Lancet Oncol. 2010, 11, 530–542. [CrossRef] [PubMed]
38. Dal Maso, L.; Zucchetto, A.; Talamini, R.; Serraino, D.; Stocco, C.F.; Vercelli, M.; Falcini, F.; Franceschi, S. Prospective Analysis of
Case-control studies on Environmental factors and health (PACE) study group Effect of obesity and other lifestyle factors on
mortality in women with breast cancer. Int. J. Cancer 2008, 123, 2188–2194. [CrossRef] [PubMed]
39. Jain, M.; Miller, A.B.; To, T. Premorbid Diet and the Prognosis of Women with Breast Cancer. JNCI J. Natl. Cancer Inst. 1994, 86,
1390–1397. [CrossRef] [PubMed]
40. Wu, J.; Zeng, R.; Huang, J.; Li, X.; Zhang, J.; Ho, J.; Zheng, Y. Dietary Protein Sources and Incidence of Breast Cancer: A
Dose-Response Meta-Analysis of Prospective Studies. Nutrients 2016, 8, 730. [CrossRef] [PubMed]
41. Zhang, S.; Folsom, A.R.; Sellers, T.A.; Kushi, L.H.; Potter, J.D. Better breast cancer survival for postmenopausal women who are
less overweight and eat less fat. The Iowa women’s health study. Cancer 1995, 76, 275–283. [CrossRef]
Int. J. Environ. Res. Public Health 2021, 18, 84 17 of 17
42. Holmes, M.D.; Wang, J.; Hankinson, S.E.; Tamimi, R.M.; Chen, W.E. Protein intake and breast cancer survival in the Nurses’
Health Study. J. Clin. Oncol. 2017, 35, 325–333. [CrossRef]
43. Borugian, M.J.; Dunn, B.; Gallagher, R.P.; Hislop, T.G.; Kim-Sing, C.; Van Patten, C.; Potter, J.D.; Sheps, S.B. Insulin, macronutrient
intake, and physical activity: Are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer
Epidemiol. Biomarkers Prev. 2004, 13, 1163–1172.
44. Holmes, M.D.; Stampfer, M.J.; Colditz, G.A.; Rosner, B.; Hunter, D.J.; Willett, W.C. Dietary factors and the survival of women with
breast carcinoma. Cancer 1999, 86, 826–835. [CrossRef]
45. Rohan, T.E.; Hiller, J.E.; McMichael, A.J. Dietary factors and survival from breast cancer. Nutr. Cancer 1993, 20, 167–177. [CrossRef]
[PubMed]
46. Virtanen, H.E.K.; Voutilainen, S.; Koskinen, T.T.; Mursu, J.; Kokko, P.; Ylilauri, M.P.T.; Tuomainen, T.P.; Salonen, J.T.; Virtanen, J.K.
Dietary proteins and protein sources and risk of death: The Kuopio ischaemic heart disease risk factor study. Am. J. Clin. Nutr.
2019, 109, 1462–1471. [CrossRef] [PubMed]
47. Song, M.; Fung, T.T.; Hu, F.B.; Willett, W.C.; Longo, V.D.; Chan, A.T.; Giovannucci, E.L. Association of animal and plant protein
intake with all-cause and cause-specific mortality. JAMA Intern. Med. 2016, 176, 1453–1463. [CrossRef] [PubMed]
48. Hernández-Alonso, P.; Salas-Salvadó, J.; Ruiz-Canela, M.; Corella, D.; Estruch, R.; Fitó, M.; Arós, F.; Gómez-Gracia, E.; Fiol, M.;
Lapetra, J.; et al. High dietary protein intake is associated with an increased body weight and total death risk. Clin. Nutr. 2016, 35,
496–506. [CrossRef] [PubMed]
49. Tremblay, F.; Lavigne, C.; Jacques, H.; Marette, A. Role of Dietary Proteins and Amino Acids in the Pathogenesis of Insulin
Resistance. Annu. Rev. Nutr. 2007, 27, 293–310. [CrossRef]
50. Gregorio, D.I.; Emrich, L.J.; Graham, S.; Marshall, J.R.; Nemoto, T. Dietary fat consumption and survival among women with
breast cancer. J. Natl. Cancer Inst. 1985, 75, 37–41.
51. Boeke, C.E.; Eliassen, A.H.; Chen, W.Y.; Cho, E.; Holmes, M.D.; Rosner, B.; Willett, W.C.; Tamimi, R.M. Dietary fat intake in
relation to lethal breast cancer in two large prospective cohort studies. Breast Cancer Res. Treat. 2014, 146, 383–392. [CrossRef]
52. Beasley, J.M.; Newcomb, P.A.; Trentham-Dietz, A.; Hampton, J.M.; Bersch, A.J.; Passarelli, M.N.; Holick, C.N.; Titus-Ernstoff, L.;
Egan, K.M.; Holmes, M.D.; et al. Post-diagnosis dietary factors and survival after invasive breast cancer. Breast Cancer Res. Treat.
2011, 128, 229–236. [CrossRef]
53. Sieri, S.; Krogh, V.; Ferrari, P.; Berrino, F.; Pala, V.; Thiébaut, A.C.M.; Tjønneland, A.; Olsen, A.; Overvad, K.; Jakobsen, M.U.; et al.
Dietary fat and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition 1–3. Am. J. Clin. Nutr.
2008, 88, 1304–1312. [CrossRef]
54. Kroenke, C.H.; Kwan, M.L.; Sweeney, C.; Castillo, A.; Caan, B.J. High-and low-fat dairy intake, recurrence, and mortality after
breast cancer diagnosis. J. Natl. Cancer Inst. 2013, 105, 616–623. [CrossRef]
55. Rose, D.P.; Connolly, J.M. Regulation of Tumor Angiogenesis by Dietary Fatty Acids and Eicosanoids. Nutr. Cancer 2000, 37,
119–127. [CrossRef] [PubMed]
56. Engeset, D.; Alsaker, E.; Lund, E.; Welch, A.; Khaw, K.T.; Clavel-Chapelon, F.; Thiébaut, A.; Chajès, V.; Key, T.J.; Allen, N.E.; et al.
Fish consumption and breast cancer risk. The European Prospective Investigation into Cancer and Nutrition (EPIC). Int. J. Cancer
2006, 119, 175–182. [CrossRef] [PubMed]
57. Welch, A.; Lund, E.; Amiano, P.; Dorronsoro, M.; Brustad, M.; Kumle, M.; Rodriguez, M.; Lasheras, C.; Janzon, L.; Jansson, J.; et al.
Variability of fish consumption within the 10 European countries participating in the European Investigation into Cancer and
Nutrition (EPIC) study. Public Health Nutr. 2002, 5, 1273. [CrossRef] [PubMed]
58. Eilander, A.; Harika, R.K.; Zock, P.L. Intake and sources of dietary fatty acids in Europe: Are current population intakes of fats
aligned with dietary recommendations? Eur. J. Lipid Sci. Technol. 2015, 117, 1370–1377. [CrossRef] [PubMed]
59. Liu, A.G.; Ford, N.A.; Hu, F.B.; Zelman, K.M.; Mozaffarian, D.; Kris-Etherton, P.M. A healthy approach to dietary fats: Under-
standing the science and taking action to reduce consumer confusion. Nutr. J. 2017, 16, 53. [CrossRef] [PubMed]
60. Shim, J.-S.; Oh, K.; Kim, H.C. Dietary assessment methods in epidemiologic studies. Epidemiol. Health 2014, 36, e2014009.
[CrossRef] [PubMed]
61. Custódio, I.D.D.; Marinho, E.d.C.; Gontijo, C.A.; Pereira, T.S.S.; Paiva, C.E.; Maia, Y.C.d.P. Impact of Chemotherapy on Diet and
Nutritional Status of Women with Breast Cancer: A Prospective Study. PLoS ONE 2016, 11, e0157113. [CrossRef]
62. Velentzis, L.S.; Keshtgar, M.R.; Woodside, J.V.; Leathem, A.J.; Titcomb, A.; Perkins, K.A.; Mazurowska, M.; Anderson, V.; Wardell,
K.; Cantwell, M.M. Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre
study. Breast Cancer Res. Treat. 2011, 128, 473–482. [CrossRef]
63. Salminen, E.; Bishop, M.; Poussa, T.; Drummond, R.; Salminen, S. Dietary attitudes and changes as well as use of supplements
and complementary therapies by Australian and Finnish women following the diagnosis of breast cancer. Eur. J. Clin. Nutr. 2004,
58, 137–144. [CrossRef]
